INTREXON CORPORATION (NYSE:XON) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item5.02. Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On March7, 2017, Geno J. Germano, President of Intrexon
Corporation (the Company), resigned from the Company effective
March10, 2017, and Randal J. Kirk cancelled plans to transition
to Executive Chairman and will remain Chairman and Chief
Executive Officer of the Company.
Item7.01. Regulation FD Disclosure.
On March 10, 2017, the Company announced the formation of
Precigen, Inc., a wholly-owned subsidiary of the Company
(Precigen), as part of an ongoing evaluation of structural
alternatives concerning the Companys business in healthcare. The
Company currently intends to consolidate all health-related
assets under this new corporate entity as it considers potential
strategic options to enhance shareholder value. A copy of the
press release announcing Mr. Germanos resignation and the
formation of Precigen is furnished with this Current Report on
Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 7.01 is being furnished and shall
not be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act whether made before or
after the date of this Current Report on Form 8-K, except as
shall be expressly set forth by specific reference in such
filing.
Item9.01. Financial Statements and Exhibits.
| (d) | Exhibits. |
| 99.1 | Press release of Intrexon Corporation. |
About INTREXON CORPORATION (NYSE:XON)
Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. Its technologies combine the principles of precision engineering, statistical modeling, automation and production at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing, or LEAP, and ActoBiotics platform. INTREXON CORPORATION (NYSE:XON) Recent Trading Information
INTREXON CORPORATION (NYSE:XON) closed its last trading session up +0.89 at 23.78 with 600,920 shares trading hands.
